

Björn L.D.M. Brücher

M.D., Ph.D., F.A.C.S, F.R.C.S. (Engl.), F.R.S.B.

Bibliography

Scientific Summary

- Editor-in-Chief *4open*
- ≥ 300 scientific international and national lectures
- ≥ 100 Invited Lectures
- ≥ 140 Peer-Reviewed Scientific Publications
- ~ 500 Impact Factor
- Google Scholar H-Index 42
- Google Scholar i10-Index 82
- Google Scholar Number of Citations 7,706
- ResearchGate Score ≥ 98%, compared to all ResearchGate members (15 million scientists)
- Grant Support € 500,000.-
- Director Theodor-Billroth-Academy® (TBA®)
- ≥ 3,800 members TBA® International Network
- Fellow & Co-Founder **International Consortium of Research Excellence INCORE**, Theodor-Billroth-Academy®

source	variables	2022	since 2017
Google Scholar	citations	7,706	2,833
	h-Index	42	30
	i10-Index	82	49

source	variables	2022
ResearchGate	Total reads	148,716
	Total citations	5,887
	h-Index	39
	RG-Interest Score	3,554
	(≥ 98% of 15 million ResearchGate scientists)	

additional variables	sum
membership predatory organizer (<i>congresses, events, webinars, etc.</i>)	0
FDA warning comments	0
retracted publications	0



Contact

Address CB, 03048 Germany
+49 179 22 77 538



b-bruecher@gmx.de



EUROPEAN ACADEMY
of Sciences and Arts




≥ 300 Lectures

≥ 140 Publications


~ 500 Impact Factor

≈ € 500,000.- Grant

Cumulative number publications 1996 – 2022



Cumulative number IF 1996 – 2022



Complex Realized Concept's

Theodor-Billroth-Academy® (TBA®)

INCORE of the TBA®

International Consortium of
Research Excellence

4open

Interdisciplinary journal

BILLROTH' Lectures

New Cancer Paradigm

Epistemology of the origin
of cancer

Research Focus

Carcinogenesis

Metastasis

Response

Interdisciplinary Approaches

Teaching Focus

Interdisciplinary Surgery

Development Student's Skills

Critical Thinking, Anatomy

Physiology & Biochemistry

Individual Learning Needs

Clinical Focus

Surgery, Cancer Surgery

Upper GI, HBPS, CRC

Peritoneal Carcinomatosis

2022

1. Brücher BLDM, Daumer M, Jamall IS (2022) PHYSICS ESSENTIALS ENABLE DEEPER UNDERSTANDING IN SIGNALING AND CROSSTALK OF THE CARCINOGENESIS PARADIGM "EPISTEMOLOGY OF THE ORIGIN OF CANCER", *Cell Physiol Biochem* 56(5), 546-572. DOI: <https://doi.org/10.33594/000000575>.
2. Lederer C, Daumer M, Gosselin RD, Jamall IS, Brücher BLDM (2022) META-ANALYSIS IN A TIME OF PANDEMIC, *4open* 5(E5), 1-2. DOI: <https://doi.org/10.1051/fopen/2022016>.
3. Brücher BLDM (2022) WAR AGAINST UKRAINE: HUMANITARIAN AID AND HOW MUCH MORALITY CAN SCIENCE BEAR?, *4open* 5(E3), 1-5. DOI: <https://doi.org/10.1051/fopen/2022012>.
4. Brücher BLDM, Brembs B, Bartsch D, Przygodzki R, Gosselin RD, Rupnik MS, Calu V, Birkenmaier, Hayden O, Schmidt A, Elias N, Stein HJ, Restrepo C, Pliquett RU, Petersen B, Spychalla A, Nguyen DH, Santos LL, Szold A, Tez M, Roviello F, Macri P, Lorocho V, Scherer MA, Pasche B, Polom K, Wesarg S, Matevossian E, Zilberstein B, Kryvoruchko IA, da Costa JMC, Nigri G, Weissig V, Ralon S, Kermansaravi M, Oleas R, Seno M, Baum M, Voskuil J, Mintz Y, Rödiger S, Schueler G, Kühn H, Delrio P, Wallner G, Rivkind A, Nieminen P, Armstrong DG, Schlegel MP, Daumer M, Ööpik V, Araujo RJC Jr., Lapeña Jr. JFF, Perkins R, Anogianakis G, Salber J, Tenne R, Jamall IS (2022) INITIATIVE ON #4OPENSOURCESTANDSFORUKRAINE SCIENTISTS AND STUDENTS, *4open* 5, E2, 1.3. DOI <https://doi.org/10.1051/fopen/2022007>.
5. Brücher BLDM (2022) IN MEMORIAM PROFESSOR DR. PHILIPP A. SCHNABEL (1953-2021), *4open* 5(7), 1-2. DOI: <https://doi.org/10.1051/fopen/2022006>.

2020

6. Scherer MA, von Freyburg A, Brücher BLDM, Jamall JS, Schmidt A, Hagedorn H (2020) COVID-19: SARS-CoV-2 SUSCEPTIBILITY IN HEALTHCARE WORKERS - CLUSTER STUDY AT A GERMAN TEACHING HOSPITAL, *4open* 3(6), 1-9. DOI: <https://doi.org/10.1051/fopen/2020006>.

5

3

7. Von Freyburg A, Hagedorn H, Brücher BLDM, Schmidt A, Scherer MA (2020) COVID-19 COHORT CLUSTER STUDY AT A TEACHING HOSPITAL, **Münchner Medizinische Wochenschrift MMW** 162(9), 64-67. IF 0.3. DOI: <https://doi.org/10.1007/s15006-020-0482-z>.
8. Brücher BLDM, Nigri G, Tinelli A, Lapeña JFF Jr., Espin-Basany E, Macri P, Matevossian E, Ralon S, Perkins R, Lück R, Kube R, da Costa JSC, Mintz Y, Tez M, Allert S, Sökmen S, Spychala A, Zilberstein B, Marusch F, Kermansaravi M, Kycler W, Vicente D, Scherer MA, Rivkind A, Elias N, Wallner G, Roviello F, Santos LL, Araujo RJC Jr., Szold A, Oleas R, Rupnik MS, Salber J, Jamall IS, Engel A for the Pandemic Surgery Guidance Consortium (PSGC) (2020) COVID-19: PANDEMIC SURGERY GUIDANCE, **4open** 3(1), 1-19. DOI: <https://doi.org/10.1051/fopen/2020002>.
9. Brücher BLDM, Deufert D (2019) GERMAN NURSING SHORTAGE - HOMEMADE BY PROFITITIS?, **4open** 2(3), 1-16. DOI: <https://doi.org/10.1051/fopen/2019007>.
10. Brücher BLDM, Jamall JS (2019) PRELUDE AND PREMISE TO THE SPECIAL ISSUE: DISRUPTION OF HOMEOSTASIS-INDUCED SIGNALING AND CROSSTALK IN THE CARCINOGENESIS PARADIGM "EPISTEMOLOGY OF THE ORIGIN OF CANCER", **4open** 2(6), 1-8. DOI: <https://doi.org/10.1051/fopen/2019005>.
11. Brücher BLDM, Jamall JS (2019) UNDERVALUED UBIQUITOUS PROTEINS, **4open** 2(7), 1-13. DOI: <https://doi.org/10.1051/fopen/2019002>.
12. Brücher BLDM, Jamall JS (2019) CHRONIC INFLAMMATION EVOKED BY PATHOGENIC STIMULUS DURING CARCINOGENESIS, **4open** 2(8), 1-22. DOI: <https://doi.org/10.1051/fopen/2018006>.
13. Brücher BLDM, Jamall JS (2019) EICOSANOIDS IN CARCINOGENESIS, **4open** 2(9), 1-34. DOI: <https://doi.org/10.1051/fopen/2018008>.
14. Brücher BLDM, Jamall JS (2019) MICROBIOME AND MORBID OBESITY INCREASE PATHOGENIC STIMULUS DIVERSITY, **4open** 2(10), 1-16. DOI: <https://doi.org/10.1051/fopen/2018007>.

2019

11

15. Brücher BLDM, Jamall JS (2019) PRECANCEROUS NICHE (PCN), A PRODUCT OF FIBROSIS WITH REMODELING BY INCESSANT CHRONIC INFLAMMATION, **4open** 2(11), 1-21. DOI: <https://doi.org/10.1051/fopen/2018009>.
16. Brücher BLDM, Jamall JS (2019) METFORMIN ALTERS SIGNALING HOMEOSTASIS, **4open** 2(12), 1-17. DOI: <https://doi.org/10.1051/fopen/2019006>.
17. Brücher BLDM, Lang F, Jamall JS (2019) NF-κB SIGNALING AND CROSSTALK IN CARCINOGENESIS, **4open** 2(13), 1-35. DOI: <https://doi.org/10.1051/fopen/2019010>.
18. Brücher BLDM, Jamall JS (2019) TRANSITION FROM NORMAL TO CANCEROUS CELL BY PRECANCEROUS NICHE (PCN) INDUCED CHRONIC CELL-MATRIX STRESS, **4open** 2(14), 1-31. DOI: <https://doi.org/10.1051/fopen/2018996>.
19. Brücher BLDM, Jamall JS (2019) SYNOPSIS - SPECIAL ISSUE: DISRUPTION OF HOMEOSTASIS-INDUCED SIGNALING AND CROSSTALK IN THE CARCINOGENESIS PARADIGM "EPISTEMOLOGY OF THE ORIGIN OF CANCER", **4open** 2(28), 1-30. DOI: <https://doi.org/10.1051/fopen/2019023>.

2018

20. Brücher BLDM (2018) SCIENCE BELONGS TO NO ONE- AND TO EVERYONE, **4open** 1(E1), 1-11. DOI: <https://doi.org/10.1051/fopen/2017501>.

2017

21. Ijaz S Jamall, Brücher BLDM (2017) SLOW BUT STEADY: CLOSING IN ON A WORLD WITHOUT CANCER, In: Imagine The Next 100 years, **The New York Academy of Sciences Magazine**, Fall 2017, Page 12. https://www.researchgate.net/publication/320942092_Slow_but_Steady_Closing_in_on_a_world_without_Cancer.

2016

22. Brücher BLDM, Yan L, Schnabel P, Daumer M, Wallace TJ, Kube R, Zilberstein B, Steele S, Jamall JS (2016) BIOTECHNOLOGIE UND KREBS (1): GENOMIK UND MICRORNA, **Chirurgische Allgemeine Zeitung** 17(1), 17-27. https://www.researchgate.net/publication/292988962_Biotechnologie_und_Krebs#fullTextFileContent.

1

1

4

23. Brücher BLDM, Yan L, Schnabel P, Daumer M, Wallace TJ, Kube R, Zilberstein B, Steele S, Jamall JS (2016) BIOTECHNOLOGIE UND KREBS (2): EPIGENETIK UND PROTEOMIK, **Chirurgische Allgemeine Zeitung** 17(3), 125-130.
https://www.researchgate.net/publication/299490429_Biotechnologie_und_Krebs_Teil_2_Epigenetik_Proteomik.
24. Brücher BLDM, Yan L, Schnabel P, Daumer M, Wallace TJ, Kube R, Zilberstein B, Steele S, Jamall JS (2016) GENOMICS, MICRORNA, EPIGENETICS, AND PROTEOMICS FOR FUTURE DIAGNOSIS, TREATMENT AND MONITORING RESPONSE IN UPPER GI CANCERS, **Clin Trans Med** 5, 1-16. DOI:
<https://doi.org/10.1186/s40169-016-0093-6>.
25. Brücher BLDM, Jamall JS (2016) SOMATIC MUTATION THEORY – WHY IT’S WRONG FOR MOST CANCERS, **Cell Physiol Biochem** 38(5), 1663-1680. DOI:
<https://doi.org/10.1159/000443106>.

2014

26. Wallace TJ, Torre T, Grob M, Avital I, Brücher BLDM, Man YG (2014) CURRENT APPROACHES, CHALLENGES AND FUTURE DIRECTIONS FOR MONITORING TREATMENT RESPONSE IN PROSTATE CANCER, **J Cancer** 5(1), 3-24. DOI: <https://doi.org/10.7150/jca.7709>.
27. McKeown E, Nelson DW, Johnson EK, Maykel JA, Stojadinovic A, Nissan A, Avital I, Brücher BLDM, Steele SR (2014) CURRENT APPROACHES AND CHALLENGES FOR MONITORING TREATMENT RESPONSE IN COLON AND RECTAL CANCER, **J Cancer** 5(1), 31-43. DOI: <https://doi.org/10.7150/jca.7987>.
28. Walker AS, Zwinterscher NP, Johnson EK, Maykel JA, Stojadinovic A, Nissan A, Brücher BLDM, Steele SR (2014) FUTURE DIRECTIONS FOR MONITORING TREATMENT RESPONSE IN COLORECTAL CANCER, **J Cancer** 5(1), 44-57. DOI:
<https://doi.org/10.7150/jca.7809>.
29. Young PE, Womeldorph CM, Johnson EK, Maykel JA, Brücher BLDM, Stojadinovic A, Avital I, Nissan A, Steele SR (2014) EARLY DETECTION OF COLORECTAL CANCER RECURRENCE IN PATIENTS UNDERGOING SURGERY WITH CURATIVE INTENT: CURRENT STATUS AND CHALLENGES, **J Cancer** 5(4), 262-271. DOI:
<https://doi.org/10.7150/jca.7988>.

14

30. Walker AS, Johnson EK, Maykel JA, Stojadinovic A, Nissan A, Brücher BLD, Champagne BJ, Steele SR (2014) FUTURE DIRECTIONS FOR THE EARLY DETECTION OF COLORECTAL CANCER RECURRENCE, **J Cancer** 5(4), 272-280. DOI: <https://doi.org/10.7150/jca.8871>.
31. Falch C, Vicente D, Häberle H, Kirschniak A, Müller S, Nissan A, Brücher BLD (2014) TREATMENT OF ACUTE ABDOMINAL PAIN IN THE EMERGENCY ROOM: A REVIEW OF THE LITERATURE, **Eur J Pain** 18(7), 902-913. DOI: <https://doi.org/10.1002/j.1532-2149.2014.00456.x>.
32. Steele SR, Bilchik A, Johnson EK, Nissan A, Peoples GE, Eberhardt JS, Kalina P, Petersen B, Brücher BLD, Protic M, Avital I, Stojadinovic A (2014) TIME-DEPENDENT ESTIMATES OF RECURRENCE AND SURVIVAL IN COLON CANCER: CLINICAL DECISION SUPPORT SYSTEM TOOL DEVELOPMENT FOR ADJUVANT THERAPY AND ONCOLOGICAL OUTCOME ASSESSMENT, **Am Surg** 80(5), 441-453. PMID: 24887722. <https://doi.org/10.1177/000313481408000514>.
33. Blom RL, Bogush T, Brücher BL, Chang AC, Davydov M, Dudko E, Leong T, Polotsky B, Swanson PE, van Rossum PS, Ruurda JP, Sagaert X, Tjalandin S, Schraepen MC, Sosef MN, van Hillegersberg R (2014) THERAPEUTIC APPROACHES TO GASTROESOPHAGEAL JUNCTION ADENOCARCINOMAS, **Ann N Y Acad Sci** 1325, 197-210. DOI: <https://doi.org/10.1111/nyas.12532>.
34. Canbay E, Yonemura Y, Brücher BLD, Baik SH, Sugarbaker PH (2014) INTRAPERITONEAL CHEMOTHERAPY AND ITS EVOLVING ROLE IN MANAGEMENT OF GASTRIC CANCER WITH PERITONEAL METASTASES, **Chin J Cancer Res** 26(1), 1-3. <https://doi.org/10.3978/j.issn.1000-9604.2014.02.06>.
35. Brücher BLD, Lyman G, van Hillegersberg R, Pollock RE, Lordick F, Yang HK, Ushijima T, Yeoh KG, Skricka T, Polkowski W, Wallner G, Verwaal V, Garofalo A, D'Ugo D, Roviello F, Steinau HU, Wallace TJ, Daumer M, Maihle N, Reid III TJ, Ducreux M, Kitagawa Y, Knuth A, Zilberstein B, Steele SR, Jamall IS (2014) IMAGINE A WORLD WITHOUT CANCER, **BMC Cancer** 14(186), 1-8. <https://doi.org/10.1186/1471-2407-14-186>.

36. Brücher BLDM, Kitajima M, Siewert JR (2014) UNDERVALUED CRITERIA IN THE EVALUATION OF MULTIMODAL TRIALS FOR UPPER GI CANCERS, **Cancer Invest** 32(10), 497-506.
<https://doi.org/10.3109/07357907.2014.958497>.
37. Brücher BLDM, Jamall IS (2014) EPISTEMOLOGY OF THE ORIGIN OF CANCER: A NEW PARADIGM, **BMC Cancer** 14(331), 1-15.
<https://doi.org/10.1186/1471-2407-14-331>.
38. Brücher BLDM, Jamall IS (2014) CELL-CELL COMMUNICATION IN TUMOR MICROENVIRONMENT, CARCINOGENESIS AND ANTICANCER TREATMENT, **Cell Physiol Biochem** 34, 213-243. DOI:
<https://doi.org/10.1159/000362978>.
39. Brücher BLDM, Itzhak A, Bilchik A, Nissan A, Stojadinovic A (2014) CARCINOMATOSIS: CYTOREDUCTION AND HEATED INTRAPERITONEAL CHEMOTHERAPY (HIPEC) VERSUS PALLIATION, In S.R.Steele et al. (eds.) **Complexities in Colorectal Surgery**. Springer Science + Business Media New York 2014. https://doi.org/10.1007/978-1-4614-9022-7_5.
- 2013
40. Brücher BLDM, Stojadinovic A, Bilchik A, Protic M, Daumer M, Nissan A, Itzhak A (2013) PATIENTS AT RISK FOR PERITONEAL SURFACE MALIGNANCY OF COLORECTAL CANCER ORIGIN: THE ROLE OF 2ND LOOK LAPAROTOMY, **J Cancer** 4(3), 262-269.
<https://doi.org/10.7150/jca.5831>.
41. Wallace T, Itzhak A, Stojadinovic A, Brücher BLDM, Cote E, Yu J (2013) MULTI-PARAMETRIC MRI-DIRECTED FOCAL SALVAGE PERMANENT INTERSTITIAL BRACHYTHERAPY FOR LOCALLY RECURRENT ADENOCARCINOMA OF THE PROSTATE: A NOVEL APPROACH, **J Cancer** 4(3), 262-269.
<https://doi.org/10.7150/jca.5419>.
42. Antonic V, Stojadinovic A, Kester KE, Weina PJ, Brücher BLDM, Itzhak A, Izadjoo M (2013) SIGNIFICANCE OF INFECTIOUS AGENTS IN COLORECTAL CANCER DEVELOPMENT, **J Cancer** 4(3), 227-240.
<https://doi.org/10.7150/jca.5835>.

43. Mazeh H, Mizrahi I, Ilyayev N, Brücher BLDM, Bilchik A, Protic M, Daumer M, Stojadinovic A, Itzhak A, Nissan A (2013) THE DIAGNOSTIC AND PROGNOSTIC ROLE OF MICRORNA IN COLORECTAL CANCER – A COMPREHENSIVE REVIEW, *J Cancer* 4(3), 281-295. <https://doi.org/10.7150/jca.5836>.
44. Falch CM, Stojadinovic A, Muller S, Kirschniak A, Hann-von-Weyhern C, Protic M, Nissan A, Bilchik A, Itzhak A, Brücher BLDM (2013) ANORECTAL MALIGNANT MELANOMA: EXTENSIVE 45-YEAR REVIEW AND PROPOSAL FOR A NOVEL STAGING CLASSIFICATION, *J Am Coll Surg* 217(2), 324-335. <https://doi.org/10.1016/j.jamcollsurg.2013.02.031>
45. Summers T, Langan RC, Nissan A, Brücher BLDM, Bilchik A, Protic M, Daumer M, Itzhak A, Stojadinovic A (2013) SERUM-BASED DNA METHYLATION BIOMARKERS IN COLORECTAL CANCER: POTENTIAL FOR SCREENING AND EARLY DETECTION, *J Cancer* 4(3), 210-216. <https://doi.org/10.7150/jca.5839>.
46. Avital I, Langan RC, Summers TA, Steele SR, Waldman SA, Backman V, Yee J, Nissan A, Young P, Womeldorph C, Mancusco P, Mueller R, Noto K, Grundfest W, Bilchik AJ, Protic M, Daumer M, Eberhardt J, Man YG, Brücher BLDM, Stojadinovic A (2013) EVIDENCE-BASED GUIDELINES FOR PRECISION RISK STRATIFICATION-BASED SCREENING (PRSBS) FOR COLORECTAL CANCER: LESSONS LEARNED FROM THE US ARMED FORCES: CONSENSUS AND FUTURE DIRECTIONS, *J Cancer* 4(3), 172-192. <https://doi.org/10.7150/jca.5834>.
47. Zilberstein B, Brücher BLDM, Coimbra BGM, Jacob CE, Barchi LC, Joaquim HG, Ceccobello I (2013) GASTRIC CANCER: ASPECTS OF MINIMAL INVASIVE TECHNIQUE, *J Gastroint Dig Syst* 3, 158. <https://doi.org/10.4172/2161-069X.1000158>.
48. Avital I, Summers TA, Steele SR, Waldman SA, Nissan A, Bilchik AJ, Protic M, Man YG, Brücher BLDM, Stojadinovic A (2013) COLORECTAL STEM CELLS AS BIOMARKERS: WHERE IT ALL STARTS? *J Surg Oncol* 107(8), 791-793. <https://doi.org/10.1002/jso.23330>.

49. Man YG, Stojadinovic A, Mason J, Avital I, Bilchik A, Brücher BLD, Nissan A, Tzadjoo M, Zhang X, Jewett A (2013) TUMOR-INFILTRATING IMMUNE CELLS PROMOTING TUMOR INVASION, *J Cancer* 4(1), 84-95. DOI: <https://doi.org/10.7150/jca.5482>.
- 2012
50. Brücher BLD, Piso P, Verwaal V, Esquivel J, Deraco M, Yonemura Y, Gonzalez-Moreno S, Pelz J, Königsrainer A, Ströhlein M, Levine EA, Morris D, Bartlett D, Glehen O, Garofalo A, Nissan A (2012) PERITONEAL CARCINOMATOSIS: OVERVIEW AND BASICS, *Cancer Invest* 30(3), 209-224. <https://doi.org/10.3109/07357907.2012.654871>.
51. Pfannenber C, Schwenger N, Brücher BLD (2012) STATE OF THE ART- BILDGEBUNG BEI PERITONEALCARCINOSE, *RoFo* 184(3), 205-213. <https://doi.org/10.1055/s-0031-1281979>.
52. Falch C, Brandtner B, Häberle H, Kirschniak A, Müller S, Brücher BLD, Königsrainer A (2012) SCHMERZTHERAPIE IN DER NOTAUFNAHME - BEISPIEL: AKUTE BAUCHSCHMERZEN, *Lege artis* 2012 2(4), 250-257. <https://doi.org/10.1055/s-0032-1325311>.
53. Klumpp BD, Aschoff P, Schwenger N, Fenchel M, Königsrainer I, Falch C, Brücher BLD, Claussen CD, Königsrainer A, Pfannberg C, Kramer U, Miller S (2012) PERITONEAL CARCINOMATOSIS: COMPARISON OF DYNAMIC CONTRAST-ENHANCED MAGNETIC RESONANCE IMAGING WITH SURGICAL AND HISTOPATHOLOGICAL FINDINGS, *Abdom Imaging* 37(5), 834-842. <https://doi.org/10.1007/s00261-011-9825-7>.
54. Klumpp BD, Schwenger N, Aschoff P, Miller S, Kramer U, Claussen CD, Brücher BLD, Königsrainer A, Pfannberg C (2012) PREOPERATIVE ASSESSEMENT OF PERITONEAL CARCINOMATOSIS: INTRINDIVIDUAL COMPARISON OF 18-FDG-PET-CT AND MRI, *Abdom Imaging* 38(1), 64-71. <https://doi.org/10.1007/s00261-012-9881-7>.

55. Königsrainer I, Zieker D, Glatzle J, Lauk O, Klimek J, Symons S, Brücher BLD, Beckert, Königsrainer A (2012) EXPERIENCE AFTER 100 PATIENTS TREATED WITH CYTOREDUCTIVE SURGERY AND HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY, **World J Gastroenterol** 18(17), 2061-2066.
<https://doi.org/10.3748/wjg.v18.i17.2061>.
56. Brücher BLD, Bilchik A, Nissan A, Avital I, Stojadinovic A (2012) TUMOR RESPONSE CRITERIA: ARE THEY APPROPRIATE? (Editorial) **Fut Oncology** 8(8), 903-906. <https://doi.org/10.2217/fon.12.78>.
57. Avital I, Brücher BLD, Nissan A, Stojadinovic A (2012) RANDOMIZED CLINICAL TRIALS FOR COLORECTAL CANCER PERITONEAL SURFACE MALIGNANCY, **Surg Clin N Am** 21(4), 665-688.
<https://doi.org/10.1016/j.soc.2012.07.004>.
58. Falch C, Königsrainer A, Brücher BLD (2012) KOLOREKTALE TUMORCHIRURGIE : IST DAS ALTER EIN HINDERNIS? **Chirurgische Allgemeine Zeitung** 13(2), 84. <https://bibliographie.uni-tuebingen.de/xmlui/handle/10900/66823>
59. Brücher BLD (2012) „BEST OF ASCO“ DEUTSCHLAND, **Chirurgische Allgemeine Zeitung** 13(9), 479-482.
https://www.researchgate.net/publication/322077593_Best_of_ASCO_Deutschland.
60. Pfannenber C, Schwenzler N, Brücher BLD (2012) State-of-the-Art-Bildgebung bei Peritonealkarzinose, *Frauenheilkunde* Up2date 6(03), 138-144. <https://doi.org/10.1055/s-0031-1284008>.
- 2011
61. Rexhepaj R, Rotte A, Gu S, Michael D, Pasham V, Wang K, Kempe DS, Ackermann TF, Brücher BLD, Fend F, Föller M, Lang F (2011) TUMOR SUPPRESSOR GENE ADENOMATOUS POLYPOSIS COLI DOWNREGULATES INTESTINAL TRANSPORT, **Pflugers Arch Eur J Phy** 461(5), 527-536.
<https://doi.org/10.1007/s00424-011-0945-2>.
62. Von Weyhern C, Brücher BLD (2011) APPLICATION OF LASER MICRODISSECTION AND QUANTITATIVE PCR TO ASSESS THE RESPONSE OF ESOPHAGEAL CANCER TO NEOADJUVANT CHEMO-RADIOTHERAPY, **Methods Mol Biol** 755, 197-202.
https://doi.org/10.1007/978-1-61779-163-5_16.

63. Königsrainer I, Beckert S, Lehmann T, Ladurner R, Brücher BLD, Königsrainer A (2011) PERITONEAL CARCINOMATOSIS, *Chirurg* 82(4), 375-380.
<https://doi.org/10.1007/s00104-010-2049-5>.
64. Königsrainer I, Beckert S, Becker S, Zieker D, Fehm T, Grischke EM, Lauk O, Glatzle J, Brücher BLD, Wallwiener D, Königsrainer A (2011) CYTOREDUCTIVE SURGERY AND HIPEC IN PERITONEAL RECURRENT OVARIAN CANCER: EXPERIENCE AND LESIONS LEARNED, *Langenbecks Arch Surg* 396(7), 1077-1081. <https://doi.org/10.1007/s00423-011-0835-2>.
65. Königsrainer I, Beckert S, Brücher BLD, Zieker D, Königsrainer A (2011) PERITONEAL CARCINOMATOSIS OF COLORECTAL CANCER: CYTOREDUCTIVE SURGERY AND HYPERTHERMICINTRAPERITONEAL CHEMOTHERAPY, *Dtsch Med Wochenschr* 136(36), 1811-1814.
<https://doi.org/10.1055/s-0031-1286108>.
66. Wagner BJ, Löb S, Lindau D, Hörzer H, Gückel B, Klein G, Glatzle J, Rammensee HG, Brücher BLD, Königsrainer A (2011) SIMVASTATIN REDUCES TUMOR CELL ADHESION, TO HUMAN PERITONEAL MESOTHELIAL CELLS BY A DECREASED EXPRESSION OF VCAM-1 AND B1 INTEGRIN, *Int J Oncol* 39(6), 1593-1600. <https://doi.org/10.3892/ijo.2011>.
67. Komanduri S, Deprez PH, Atasoy A, Hofmann G, Pokieser P, Ba-Ssalamah A, Collard JM, Wijnhoven BP, Verhage RJ, Brücher BLD, Schuhmacher C, Feith M, Stein H (2011) BARRETT'S ESOPHAGUS: TREATMENTS OF ADENOCARCINOMA I, *Ann N Y Acad Sci* 1232(1), 248-264.
<https://doi.org/10.1111/j.1749-6632.2011.06055.x>.
68. Twaddell WS, Wu PC, Verhage RJ, Feith M, Ilson DH, Schuhmacher CP, Luketich JD, Brücher BLD, Vallböhmer D, Hofstetter WL, Krasna MJ, Kandioler D, Schneider PM, Wijnhoven BP, Sontag SJ (2011) BARRETT'S ESOPHAGUS: TREATMENTS OF ADENOCARCINOMA II, *Ann N Y Acad Sci* 1232(1), 265-291. <https://doi.org/10.1111/j.1749-6632.2011.06056.x>.
69. Schneider JH, Küper M, Königsrainer A, Brücher BLD (2010) TRANSIENT LOWER ESOPHAGEAL SPHINCTER RELAXATION AND CONSECUTIVE ESOPHAGEAL MOTOR RESPONSE, *J Surg Res* 159(2), 714-719.
<https://doi.org/10.1172/JCI109667>.

70. Schneider JH, Küper MA, Königsrainer A, Brücher BLDM (2010) NON-ACID GASTROESOPHAGEAL REFLUX MEASURED USING MULTICHANNEL INTRALUMINAL IMPEDANCE IN OLDER PATIENTS, *J Gastrointest Surg* 1, 17-23. <https://doi.org/10.1007/s11605-009-1017-1>.
71. Pühringer-Oppermann F, Sarbia M, Ott N, Brücher BLDM (2010) THE PREDICTIVE VALUE OF GENES OF THE TGF- β 1 PATHWAY IN MULTIMODALLY TREATED SQUAMOUS CELL CARCINOMA OF THE ESOPHAGUS, *Int J Colorectal Dis* 25(4), 515-521. <https://doi.org/10.1007/s00384-009-0867-z>.
72. Zieker D, Königsrainer I, Tritschler I, Löffler M, Beckert S, Traub F, Nieselt K, Bühler S, Weller M, Gaeddcke J, Taichman RS, Northoff H, Brücher BLDM, Königsrainer A (2010) P PHOSPHOGLYCERATE KINASE1 A PROMOTING ENZYME FOR PERITONEAL DISSEMINATION IN GASTRIC CANCER, *Int J Cancer* 126(6), 1513-1520. <https://doi.org/10.1002/ijc.24835>.
73. Küper MA, Kratt T, Kramer MK, Zdichavsky M, Schneider JH, Glatzle J, Stücker D, Königsrainer A, Brücher BLDM (2010) EFFORT, SAFETY, AND FINDINGS OF ROUTINE PREOPERATIVE ENDOSCOPIC EVALUATION OF MORBIDITY OBESE PATIENTS UNDERGOING BARIATRIC SURGERY, *Surg Endosc* 24(8), 1996-2001. <https://doi.org/10.1007/s00464-010-0893-5>.
74. Brücher BLDM, Königsrainer A (2010) PERITONEALCARCINOSE, *Chirurgische Allgemeine Zeitung* 11(1), 17-31. https://www.researchgate.net/publication/274705486_Die_Peritonealkarzinose#fullTextFileContent.
75. Brücher BLDM (2010): THEODOR-BILLROTH-ACADEMY®, *BDC Mitteilungen* 6, 322-325. <https://www.theodor-billroth-akademie.com/assets/2010-Der-Chirurg-BDC-TBA-Mitteilung.pdf>.

76. Zieker D, Königsrainer I, Weinreich J, Beckert S, Glatzle J, Nieselt K, Bühler S, Löffler M, Gaedcke J, Northoff H, Manheim JG, Wiehr S, Pichler PJ, von-Weyhern C, Brücher BLD, Königsrainer A (2010) PHOSPHOGLYCERATE KINASE1 PROMOTING TUMOR PROGRESSION AND METASTASIS IN GASTRIC CANCER – DETECTED IN A TUMOUR MOUSE MODEL USING POSITRON EMISSION TOMOGRAPHY / MAGNETIC RESONANCE IMAGING, *Cell Physiol Biochem* 26(2), 147-154.

<https://doi.org/10.1159/000320545>.

77. Brücher BLD (2010) THEODOR-BILLROTH-ACADEMY®: ACTIVE PROMOTION OF FUTURE SURGEONS, *Zentralblatt Chir* 135(5), 147-154.

<https://doi.org/10.1055/s-0030-1247465>.

2009

78. Löb S, Königsrainer A, Zieker D, Brücher BLD, Rammensee HG, Oplez G, Terness P (2009) IDO1 AND IDO2 ARE EXPRESSED IN HUMAN TUMORS: LEVO- BUT NOT DEXTRO-1-METHYL TRYPTOPHAN INHIBITS TRYPTOPHAN CATABOLISM, *Cancer Immunol Immun* 58(1), 153-157. <https://doi.org/10.1007/s00262-008-0513-6>.

79. Pfannenber C, Königsrainer I, Aschoff P, Öksüz M, Zieker D, Beckert S, Symons S, Nieselt K, Glatzle J, Brücher BLD, Claussen CD, Königsrainer A (2009) 18F-FDG-PET/CT TO SELECT PATIENTS WITH PERITONEAL CARCINOMATOSIS FOR CYTOREDUCTIVE SURGERY AND HYPERThERMIC INTRAPERITONEAL CHEMOTHERAPY, *Ann Surg Oncol* 16(5), 1295-1303. <https://doi.org/10.1245/s10434-009-0387-7>.

80. Schneider JME, Brücher BLD, Küper M, Saemann K, Königsrainer A, Schneider JH (2009) MULTICHANNEL INTRALUMINAL IMPEDANCE MEASUREMENT OF GASTRO-ESOPHAGEAL REFLUX IN PATIENTS WITH DIFFERENT STAGES OF MORBID OBESITY, *Obes Surg* 19(11), 1522-1529.

<https://doi.org/10.1007/s11695-008-9624-6>.

81. Königsrainer I, Zieker D, Beckert S, von Weyhern C, Löb S, Falch C, Brücher BLD, Königsrainer A, Glatzle J (2009) LOCAL PERITONECTOMY HIGHLY ATTRACTS FREE FLOATING INTRAPERITONEAL COLORECTAL TUMOUR CELLS IN A RAT MODEL, *Cell Physiol Biochem* 23(4-6), 371-378.

<https://doi.org/10.1159/000218183>.

12

82. Falch C, Kratt T, Beckert S, Kirschniak A, Zieker D, Königsrainer I, Löb S, Hartmann JT, Königsrainer A, Brücher BLDM (2009) SURGERY OF COLORECTAL CARCINOMA IN PATIENTS ABOVE 80 YEARS, *Onkologie* 32 (1-2), 10-16.
<https://doi.org/10.1159/000184580>.
83. Brücher BLDM, Keller G, Werner M, Müller U, Lassmann S, Cabras AC, Fend F, Busch R, Stein H, Allescher HD, Molls M, Siewert JR, Höfler H, Specht K (2009) USING Q-RT-PCR TO MEASURE CYCLIN D1, TS, TP, DPD, AND HER-2/NEU AS PREDICTORS FOR RESPONSE, SURVIVAL, AND RECURRENCE IN PATIENTS WITH ESOPHAGEAL SQUAMOUS CELL CARCINOMA FOLLOWING RADIOCHEMOTHERAPY, *Int J Colorectal Dis* 24(1), 69-77.
<https://doi.org/10.1007/s00384-008-0562-5>.
84. Schneider JH, Küper M, Königsrainer A, Brücher BLDM (2009) TRANSIENT LOWER ESOPHAGEAL SPHINCTER RELAXATION AND CONSECUTIVE ESOPHAGEAL MOTOR RESPONSE IN HUMANS AND IN AN ANIMAL MODEL, *Obes Surg* 19(5), 595-600.
<https://doi.org/10.1016/j.jss.2009.02.021>.
85. Tannapfel A, Brücher BLDM, Schlag PM (2009) PERITONEAL MESOTHELIOMA, *Onkologe* 15, 250-260.
<https://doi.org/10.1007/s00761-009-1576-5>.
86. Königsrainer I, Zieker D, Glatzle J, Brücher BLDM, Nadalin S, Königsrainer A (2009) SURGICAL STRATEGY IN HILARY CHOLANGIOCARCINOMA, *J Gastroenterol Hepatol Erkr.*
https://www.researchgate.net/publication/222009658_Surgical_Strategy_in_hilary_cholangiocarcinoma.
87. Königsrainer A, Königsrainer I, Brücher BLDM, Nadalin S (2009) CHIRURGISCHE STRATEGIE BEI KLATSKIN-TUMOREN, *Pankreas und Galle*.
88. Brücher BLDM, Swisher S, Königsrainer A, Zieker D, Hartmann J, Stein HJ, Kitagawa Y, Law S, Ajani JA (2009) RESPONSE TO PREOPERATIVE THERAPY IN UPPER GASTROINTESTINAL CANCERS, *Ann Surg Oncol* 16(4), 878-886.
<https://doi.org/10.1245/s10434-009-0315-x>.

2008

89. Brücher BLDM (2009) ESOPHAGEAL SQUAMOUS CELL CARCINOMA: PRE-OPERATIVE COMBINED RADIOCHEMOTHERAPY FROM A SURGICAL ONCOLOGICAL VIEWPOINT, *Chirurg* 80(11), 1011-1018.
<https://doi.org/10.1007/s00104-009-1733-9>.
90. Reim D, Weirich G, Neu B, Monther B, Präuer H, Brücher BLDM (2008) SYNCHRONOUS ADENOCARCINOMA OF THE LUNG AND A NEUROENDOCRINE CARCINOMA OF THE ILEUM, *Int J Colorectal Dis* 23(3), 325-327.
<https://doi.org/10.1007/s00384-007-0412-x>.
91. Matevossian E, Brücher BLDM, Nährig J, Feußner H, Thorban S, Hüser N (2008) GLOMUS TUMOR OF THE STOMACH SIMULATING A GASTRO INTESTINAL STROMAL TUMOR: A CASE REPORT WITH SURGICAL, HISTOLOGICAL, IMMUNOHISTOCHEMICAL ASPECTS AND REVIEW OF LITERATURE, *Case Reports in Gastroenterology* 2, 1-5. <https://doi.org/10.1159/000112862>.
92. Gerg M, Kopitz C, Schaten S, Tschukes S, Bandapalli OR, Stangl M, Hann von Weyhern CW, Brücher BLDM, Edwards DR, Brand K, Krüger A (2008) DISTINCT FUNCTIONALITY OF TUMOR CELL-DERIVED GELATINASES DURING FORMATION OF LIVER METASTASES, *Mol Cancer Res* 6(3), 341-351.
<https://doi.org/10.1158/1541-7786.MCR-07-2032>.
93. Zieker D, Königsrainer I, Traub F, Nieselt K, Knapp B, Schillinger C, Stirnkorb C, Northoff H, Kupka S, Brücher BLDM, Königsrainer A (2008) PGK1 EXPRESSION AS A PREDICTOR FOR PERITONEAL DISSEMINATION OF GASTRIC CANCER, *Cell Physiol Biochem* 21(5-6), 429-436.
<https://doi.org/10.1159/000129635>.
94. Kopp HG, Patel S, Brücher BLDM, Hartmann JT (2008) POTENTIAL COMBINATION OF CHEMOTHERAPY APPROACHES FOR ADVANCED ADULT TYPE SOFT TISSUE SARCOMA, *Am J Dermatopath* 9(4), 207-212.
<https://doi.org/10.2165/00128071-200809040-00001>.
95. Kranzfelder M, Seidl S, Dobritz M, Brücher BLDM (2008) CASE REPORT OF AN AMELANOTIC ESOPHAGEAL MALIGNANT MELANOMA, *Case Reports in Gastroenterology* 2, 224-231.
<https://doi.org/10.1159/000137376>.

10

96. Lorenzen S, Brücher BLDM, Zimmermann F, Riera J, Schuster T, Roethling N, Peschel C, Siewert JR, Molls M, Lordick F (2008) NEOADJUVANT INFUSION 5-FLUOROURACIL AND ESCALATING DOSES OF OXALIPLATIN GIVEN WEEKLY WITH CONCURRENT RADIATION IN LOCALLY ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA: RESULTS OF A PHASE I/II TRIAL, *Br J Cancer* 99(7), 1020-1026.
<https://doi.org/10.1038/sj.bjc.6604659>.
97. Königsrainer I, Aschoff P, Zieker D, Beckert S, Glatzle J, Pfannenberger C, Miller S, Hartmann JT, Schröder TH, Brücher BLDM, Königsrainer A (2008) SELECTION CRITERIA IN PERITONEAL CARCINOMATOSIS, *Zentralblatt Chir* 133(5), 468-472.
<https://doi.org/10.1055/s-2008-1076973>.
98. Küper MA, Schmidt D, Kramer KM, Königsrainer I, Zdichavsky M, Granderath F, Königsrainer A, Brücher BLDM (2008) MORBID OBESITY AND SUBSEQUENT PANCREATIC CANCER: PYLORUS-PRESERVING PANCREATODUODENECTOMY AFTER LAPAROSCOPIC SLEEVE GASTRECTOMY, *Obes Surg* 19(3), 385-388. <https://doi.org/10.1007/s11695-008-9679-4>.
99. Löb S, Terness P, Zieker D, Brücher BLDM, Rammensee H, Königsrainer A (2008), TARGETING IDO FOR TUMOR THERAPY: BETWEEN REALITY AND WISHFUL THINKING, *Wien Klin Wochenschr* 120(15-16), P 108.
- 2007
100. Brücher BLDM, Sarbia M, Oestreicher E, Molls M, Burian M, Biemer E, Stein HJ (2007) SQUAMOUS CELL CARCINOMA AND ZENKER DIVERTICULUM, *Dis Esophagus* 20, 75-58.
<https://doi.org/10.1111/j.1442-2050.2007.00648.x>.
101. Möbius C, Freire J, Becker I, Feith M, Brücher BLDM, Hennig M, Siewert JR, Stein HJ (2007) VEGF-C EXPRESSION IN SQUAMOUS CELL CARCINOMA AND ADENOCARCINOMA OF THE ESOPHAGUS, *World J Surg* 31(9), 1768-1772.
<https://doi.org/10.1007/s00268-006-0373-1>.

102. Kopitz C, Gerg M, Ister D, Pennington CJ, Hauser S, Krell HW, Brew K, Nagase H, Stangl M, von Weyhern CWH, Brücher BLD, Coussens LM, Edwards DR, Krüger A (2007) TISSUE INHIBITOR OF METALLOPROTEINASES-1 PROMOTES LIVER METASTASIS BY INDUCTION OF HEPATOCYTE GROWTH FACTOR SIGNALING, **Cancer Research** 67(18), 8615-8623.
<https://doi.org/10.1158/0008-5472.CAN-07-0232>.
103. Sarbia M, Pühringer-Oppermann F, Brücher BLD (2007) THE PREDICTIVE VALUE OF MOLECULAR MARKERS (P53, EGFR, ATM, CHK2) IN MULTIMODAL TREATED ESOPHAGEAL SQUAMOUS CELL CARCINOMA, **Br J Cancer** 97(10), 1404-1408.
<https://doi.org/10.1038/sj.bjc.6604037>.
- 2006
104. Brücher BLD, Becker K, Lordick F, Fink U, Sarbia M, Stein HJ, Busch R, Zimmermann F, Molls M, Höfler H, Siewert JR (2006) HISTOPATHOLOGICAL RESPONSE BY RESIDUAL TUMOR CELL QUANTIFICATION IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA AND NEOADJUVANT THERAPY AND ITS CLINICAL USE, **Langenbecks Arch Chir** 35, 131-133.
<https://doi.org/10.1002/cncr.21850>.
105. von Rahden BHA, Langner C, Brücher BLD, Siewert JR, Stein HJ, Sarbia M (2006) NO ASSOCIATION OF PRIMARY ADENOCARCINOMAS OF THE SMALL BOWEL WITH EPSTEIN-BARR-VIRUS INFECTION, **Mol Carcinog** 45(4), 349-352.
<https://doi.org/10.1002/mc.2016>.
106. von Rahden BHA, Brücher BLD, Langner C, Hartl S, Theisen J, Siewert JR, Stein HJ, Sarbia M (2006) EXPRESSION OF COX-1 AND 2, PROSTAGLANDIN SYNTHASE AND TRANSFORMING GROWTH FACTOR BETA1, AND THEIR RELATIONSHIP WITH VASCULAR ENDOTHELIAL GROWTH FACTORS A AND C, IN PRIMARY ADENOCARCINOMA OF THE SMALL INTESTINE, **Br J Surgery** 93, 1424-1432.
<https://doi.org/10.1002/bjs.5426>.
107. Siewert JR, Lordick F, Ott K, Brücher BLD, Rosenberg R (2006) CURATIVE VERSUS PALLIATIVE STRATEGIES IN LOCOREGIONAL RECURRENCE OF GASTROINTESTINAL MALIGNANCIES, **Chirurg** 77(3), 227-235. <https://doi.org/10.1007/s00104-006-1163-x>.

108. Brücher, BLDM, Geddert H, Langner C, Höfler H, Fink U, Siewert JR, Sarbia M (2006) HYPERMETHYLATION OF HMLH1, HPP1, P14ARF, P16INK4A, AND APC IN PRIMARY ADENOCARCINOMAS OF THE SMALL BOWEL, *Int J Cancer* 119, 1298-1302. <https://doi.org/10.1002/ijc.21990>.
109. von Rahden BHA, Brücher BLDM, Sarbia M (2006) ESOPHAGEAL SQUAMOUS CELL CARCINOMA WITH ENTIRELY INTRAMURAL GROWTH PATTERN, *Virchows Archiv* 448 (6), 862-866. <https://doi.org/10.1007/s00428-006-0185-6>.
110. Zimmermann F, Lordick F, Sarbia M, Brücher BLDM, Nüssler V (2006) DIAGNOSTIK UND THERAPIE DES OESOPHAGUSCARCINOMS, *In Fo Onkologie* 9 (1), 67-78.
111. Brücher BLDM, Becker K, Lordick F, Fink U, Sarbia M, Stein HJ, Busch R, Molls M, Höfler H, Siewert JR (2006) THE CLINICAL IMPACT OF HISTOPATHOLOGICAL RESPONSE ASSESSMENT BY RESIDUAL TUMOR CELL QUANTIFICATION IN ESOPHAGEAL SQUAMOUS CELL CARCINOMAS, *Cancer* 106(10), 2119-2127. <https://doi.org/10.1002/cncr.21850>.
112. Brücher BLDM (2006) ASSESSMENT OF HISTOPATHOLOGICAL RESPONSE IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA AFTER NEOADJUVANT THERAPY: WHAT FOR? *American Journal of Hematology/Oncology (AJOR)* 5(10), 619-624. https://www.researchgate.net/publication/222009632_Assessment_of_histopathological_response_in_esophageal_squamous_cell_carcinoma_after_neoadjuvant_therapy_What_for#fullTextFileContent.
- 2005
113. Brücher BLDM, Stock K, Ungeheuer A, Erdmann J, Lersch C (2005) NONINVASIVE POWER DOPPLER-MEDIATED DIAGNOSIS OF CATHETER LEAKAGE IN A TOTALLY IMPLANTED VENOUS ACCESS PORT, *J Ultrasound Med* 24(1), 109-111. <https://doi.org/10.7863/jum.2005.24.1.109>.

114. Stein HJ, Feith M, Brücher BLDM, Nährig J, Siewert JR (2005) EARLY ESOPHAGEAL SQUAMOUS CELL AND ADENOCARCINOMA: PATTERN OF LYMPHATIC SPREAD AND PROGNOSTIC FACTORS FOR LONG TERM SURVIVAL AFTER SURGICAL RESECTION, *Ann Surg*, 242(4), 566-573. <https://doi.org/10.1097/01.sla.0000184211.75970.85>.
115. Lordick F, Zimmermann F, Brücher BLDM, Riera J, Becker K, Seroneit T, Röthling N, Molls M, Siewert JR, Peschel C (2005) PHASE I STUDY AND FIRST EFFICACY RESULTS OF CONTINUOUS INFUSION WITH 5-FLUOROURACIL AND ESCALATING DOSES OF WEEKLY OXALIPLATIN COMBINED WITH CONCURRENT RADIATION AS NEOADJUVANT TREATMENT IN LOCALLY ADVANCED OESOPHAGEAL SQUAMOUS CELL CARCINOMA, *Onkologie* 28, 1-275.
- 2004
116. Wieder H, Brücher BLDM, Bauer M, Fink U, Avril N, Stein HJ, Werner M, Zimmermann F, Siewert JR, Schwaiger M, Weber W (2004) TIME COURSE OF TUMOR METABOLIC ACTIVITY DURING CHEMORADIO THERAPY OF ESOPHAGEAL SQUAMOUS CELL CARCINOMA AND RESPONSE TO TREATMENT, *J Clin Oncol* 22, 900-908. <https://doi.org/10.1200/JCO.2004.07.122>.
117. Brücher BLDM, Stein HJ, Zimmermann F, Werner M, Sarbia M, Busch R, Dittler HJ, Molls M, Fink U, Siewert JR (2004) RESPONDERS BENEFIT FROM NEOADJUVANT RADIOCHEMOTHERAPY IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA: RESULTS OF A PROSPECTIVE PHASE-II-TRIAL, *EJSO - Eur J Surg Oncol* 30(9), 963-971. <https://doi.org/10.1016/j.ejso.2004.06.008>.
- 2003
118. Oestreicher E, Koch O, Brücher BLDM (2003) PFÄHLUNGSVERLETZUNG DES HALSES, *HNO* 51(10), 829-832. <https://doi.org/10.1007/s00106-003-0828-8>.

2

1

2002

119. Brücher BLDM, Stein HJ, Werner M, Siewert JR (2002) LYMPHANGIOSIS CARCINOMATOSA: UNABHÄNGIGER PROGNOSEFAKTOR BEI PATIENTEN MIT PLATTENEPITHEL CARCINOM DES OESOPHAGUS, In: Chirurgisches Forum 2002. Deutsche Gesellschaft für Chirurgie 31. **Springer, Berlin, Heidelberg.** https://doi.org/10.1007/978-3-642-56158-0_28.

2001

120. Brücher BLDM, Stein HJ, Bartels H, Feussner H, Siewert JR (2001) ACHALASIA AND ESOPHAGEAL CANCER: INCIDENCE, PREVALENCE AND PROGNOSIS, **World J Surg** 25(6), 745-749. <https://doi.org/10.1007/s00268-001-0026-3>.
121. Brücher BLDM, Roder JD, Busch R, Fink U, Stein HJ, Werner M, Siewert JR (2001) NEW ASPECTS IN PROGNOSTIC FACTORS IN ADENOCARCINOMAS OF THE SMALL BOWEL, **Hepatogastroenterology** 48(39), 727-732. PMID 11462914.
122. Brücher BLDM, Weber W, Bauer M, Fink U, Avril N, Stein HJ, Werner M, Zimmermann F, Siewert JR, Schwaiger M (2001) NEOADJUVANT THERAPY OF ESOPHAGEAL SQUAMOUS CELL CARCINOMA: RESPONSE EVALUATION BY POSITRON EMISSION TOMOGRAPHY, **Ann Surg** 233(3), 300-309. <https://doi.org/10.1097/00000658-200103000-00002>.
123. Brücher BLDM, Stein HJ, Werner M, Siewert JR (2001) LYMPHATIC VESSEL INFILTRATION AS AN INDEPENDENT PROGNOSTIC FACTOR IN IN PATIENTS WITH A PRIMARY RESECTED TUMOR WITH ESOPHAGEAL SQUAMOUS CELL CARCINOMA, **Cancer** 92(8), 2228-2233. [https://doi.org/10.1002/1097-0142\(20011015\)92:8<2228::aid-cnrcr1567>3.0.co;2-4](https://doi.org/10.1002/1097-0142(20011015)92:8<2228::aid-cnrcr1567>3.0.co;2-4).
124. Stein HJ, Brücher BLDM, Sandler A, Siewert JR (2001) ESOPHAGEAL CANCER: PATIENT EVALUATION AND PRE-TREATMENT STAGING, **J Surg Oncol** 10, 103-111. [https://doi.org/10.1016/s0960-7404\(01\)00023-8](https://doi.org/10.1016/s0960-7404(01)00023-8).

No# publications

1

6

125. Siewert JR, Stein HJ, Feith M, Brücher BLDM, Bartels H, Fink U (2001) HISTOLOGIC TUMOR TYPE IS AN INDEPENDENT PROGNOSTIC PARAMETER IN ESOPHAGEAL CANCER: LESSONS LEARNED FROM MORE THAN 1000 CONSECUTIVE RESECTIONS AT A SINGLE CENTER IN THE WESTERN WORLD, *Ann Surg* 234(3), 360-369. <https://doi.org/10.1097/00000658-200109000-00010>.

2000

126. Zantl N, Stein HJ, Brücher BLDM, Bartels H, Siewert JR (2000) ISCHEMIC SPINAL CORD SYNDROME AFTER TRANSTHORACIC ESOPHAGECTOMY: TWO CASES OF A RARE NEUROLOGIC COMPLICATION, *Dis Esophagus* 13, 328-332. <https://doi.org/10.1046/j.1442-2050.2000.00142.x>.

127. Brücher BLDM, Weber W, Fink U, Bauer M, Molls M., Siewert JR, Schwaiger M (2000) PREDICTIVITY OF PET IN THE RESPONSE EVALUATION AFTER NEOADJUVANTRTX/CTX IN ESOPHAGEAL CANCER, *J Cancer Res Clin Oncol* 126, 33.

1999

128. Brücher BLDM, Weber W, Bauer M, Fink U, Werner M, Molls M, Schwaiger M, Siewert JR (1999) PRÄDIKTIVITÄT VON 18-FDG-PET IM MONITORING DES RESPONSE BEI NEOADJUVANT VORBEHANDELTEN PLATTENEPIHEL CARCINOMEN DES OESOPHAGUS, *Langenbecks Arch Chir.*

129. Helmberger H, Sorger N, Brücher LDM, Matzen K, Fink U, Gerhardt P (1999) POSITIVE ORAL CONTRAST AGENT (MAGNEVIST ENTERAL) FOR MR STAGING OF ADVANCED MASSES OF THE UPPER GI TRACT, *European Radiology* Sonderheft 1, 950.

1998

130. Brücher BLDM, Roder JD, Fink U, Stein HJ, Busch R, Siewert JR (1998), PROGNOSTIC FACTORS IN RESECTED PRIMARY SMALL BOWEL TUMORS, *Dig Surgery* 15, 42-51. <https://doi.org/10.1159/000018585>.

131. Stein HJ, Brücher BLDM, Fink U, Siewert JR (1998) PROXIMALES ÖSOPHAGUSCARCINOM: OPERIEREN, BESTRAHLEN ODER MULTIMODALES VORGEHEN? *Münchener Medizinische Wochenschrift MWW* 19, 38-44.

2

2

10

132. Stein HJ, Fink U, Brücher BLD, Etter M, Dittler HJ, Siewert JR (1998) ÖSOPHAGUSKARZINOM, **Klinik der Gegenwart** Juni 1998.
133. Brücher BLD, Stein HJ, Feussner H, Bartels H, Siewert JR (1998) ACHALASIE UND CARCINOM DES OESOPHAGUS: INZIDENZ, PRÄVALENZ UND PROGNOSE, **Langenbecks Arch Chir** 115, 1357-1359.
134. Siewert JR, Brücher BLD, Stein HJ, Fink U (1998) OESOPHAGUSCARCINOM – RÜCKFALLRISIKO SYSTEMATISCH ODER LOKAL – WELCHE PERIOPERATIVEN MASSNAHMEN HABEN EINEN ERFOLG GEBRACHT? **Langenbecks Arch Chir** 115, 290-294.
135. Brücher BLD, Weber W, Fink U, Schwaiger M, Molls M, Siewert JR (1998) FDG-PET IN THE RESPONSE EVALUATION AFTER NEOADJUVANT THERAPY IN ESOPHAGEAL CANCER, **J Cancer Res Clin Oncol** 124, 26.
136. Stein HJ, Brücher BLD, Fink U, Molls M, Dittler HJ, Bartels H, Siewert JR (1998) MULTIMODAL THERAPY FOR LOCALLY ADVANCED SQUAMOUS CELL ESOPHAGEAL CANCER LOCATED AT OR ABOVE THE LEVEL OF THE TRACHEAL BIFURCATION: INTERIM REPORT OF A PHASE II TRIAL, **J Cancer Res Clin Oncol** 124, 103.
137. Brücher BLD, Stein HJ, Bartels H, Siewert JR (1998) ESOPHAGEAL CARCINOMA IN PATIENTS WITH ACHALASIA: INCIDENCE, PREVALENCE AND PROGNOSIS, **Can J Gastroenterol** 12(Suppl B), 454.
138. Brücher BLD, Weber W, Stein HJ, Schwaiger M, Molls M, Siewert JR (1998) FDG-PET IN THE RESPONSE EVALUATION AFTER NEOADJUVANT TREATMENT OF LOCAL ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMAS, **Can J Gastroenterol** 12, 455.
139. Brücher BLD, Fink U, Gofferje M, Molls M, Helmberger H, Dittler HJ, Bartels H, Stein HJ, Siewert JR (1998) AN INTERIM REPORT OF PHASE II TRIAL OF MULTIMODAL TREATMENT IN LOCALLY ADVANCED SQUAMOUS CELL ESOPHAGEAL CANCER LOCATED AT AND ABOVE THE TRACHEAL BIFURCATION, **Can J Gastroenterol** 12, 456.
140. Helmberger H, Hogg M, Brücher BLD, Kirsten R, Fink U, Gerhardt P (1997) MÖGLICHKEITEN ABDOMINALER TUMORVOLUMETRIE, **Röntgenpraxis** 50, 11-17. PMID: 9132974.

1997

141. Helmberger H, Bartzsch O, Brücher BLDM, Dittler HJ, Schulte B, Fink U, Gerhardt P (1997) ADENOCARCINOMA OF THE GASTROESOPHAGEAL JUNCTION: EVALUATION OF THE RESPONSE TO NEOADJUVANT CHEMOTHERAPY WITH SPIRAL CT AND MRI, **European Radiology** 7, 245.
142. Hess U, Brücher BLDM., Cavallaro A, Hannig C, Stein HJ, Ott R (1997) INTRAMURAL ESOPHAGEAL HEMATOMA AFTER CARDIOVERSION, **Dis Esophagus** 10, 225-228. <https://doi.org/10.1093/dote/10.3.225>.
143. Helmberger H, Bartzsch O, Brücher BLDM, Dittler HJ, Schulte B, Fink U, Gerhardt P (1997) SPIRAL-CT UND MRT ZUR RESPONSEBEURTEILUNG VON ADENOKARZINOMEN DES GASTRO-ÖSOPHAGEALEN ÜBERGANGS UNTER NEOADJUVANTER CHEMOTHERAPIE, **RoFo - Fortschr Röntgenstr** 166(1), 40-41.

1996

144. Brücher BLDM, Strack HH (1996) AGENESIE DES DORSALEN MESENTERIUMS, **Chirurgische Praxis** 50, 23-27. <https://doi.org/>

Actual realized Basic Science Pilot Project

2021- 11
2022- 09

“Development and validation of 3R-compliant bioevaluation platform for the realistic investigation of surgical anastomotic sutures on ex vivo porcine small intestine for the analysis of novel anastomotic adhesives”

Methods

1. Establishment of an in vitro and in vivo flow system with tissue glue currently used clinically
2. Testing of new isocyanate-terminated polymer NCO-sP(EO-stat-PO)

✓ Evaluation Master Thesis 1.0 (by two Reviewers)

➤ Access Thesis (hyperlink) [Download Master Thesis 09_2022](#)

No# publications

1

Σ 152

Collaboration

CoBoMu Project

- CTK, **Cottbus**
- University of **Bochum**
- TUM, **Munich**

Global Conception

Web Link Project

“Physico Chemical characterization & biological assessment of novel polymer based dendrimer tissue adhesives”

2013

145. Steele SR, Bilchik A, Johnson EK, Nissan A, Peoples GE, Eberhardt JS, Kalina P, Petersen B, Brücher BLD, Protic M, Avital I, Stojadinovic A (2013) TIME-DEPENDENT ESTIMATES OF RECURRENCE AND SURVIVAL IN COLON CANCER: CLINICAL DECISION SUPPORT SYSTEM TOOL DEVELOPMENT FOR ADJUVANT THERAPY AND ONCOLOGICAL OUTCOME ASSESSMENT, *J Clin Oncol* 31(15), suppl, e14500-e1450. DOI: <https://ascopubs.org/doi/abs/10.1200/jco.2013.31.15.suppl.e14500>

146. Brücher BLD, Puehringer-Oppermann F, Ott N, Hartmann JT, Koenigsrainer A, Sarbia M (2008) GENES OF THE TGF β 1 PATHWAY IN MULTIMODALLY TREATED SQUAMOUS CELL CARCINOMA OF THE ESOPHAGUS, *J Clin Oncol* 26(15), 22152-22152. DOI: <https://ascopubs.org/doi/abs/10.1200/jco.2008.26.15.suppl.22152>.

2008

147. Hartmann JT, Bauer S, Schaedel S, Meisinger I, Brücher BLD, Kasper B, Kopp H, Kanz L, Mayer F, V. Gruenwald V (2008) A NON-COMPARATIVE PHASE II STUDY OF PEMETREXED IN PATIENTS WITH PRETREATED SOFT TISSUE SARCOMA: GERMAN SARCOMA GROUP/AIO 005, *J Clin Oncol* 26(15), 10575-10575. DOI: <https://ascopubs.org/doi/abs/10.1200/jco.2008.26.15.suppl.10575>.

148. Zieker D, Koenigsrainer I, Traub F, Nieselt K, Stirnkorb C, Kupka S, Fend F, Hartmann JT, Northoff H, Brücher BLD, Koenigsrainer A (2008) PGK1 A PROSPECT MARKER FOR PERITONEAL DISSEMINATION IN GASTRIC CANCER, *J Clin Oncol* 26(15), 22171-22171. DOI: <https://ascopubs.org/doi/abs/10.1200/jco.2008.26.15.suppl.22171>.

2007

149. Brücher BLD, Puehringer-Oppermann F, Sarbia M (2007) SMAD4 IS PREDICTIVE FOR RESPONSE IN NEOADJUVANT TREATED ESOPHAGEAL SQUAMOUS CELL CARCINOMA, *J Clin Oncol* 25(18), 4591-4591. DOI: <https://ascopubs.org/doi/abs/10.1200/jco.2007.25.18.suppl.4591>.

2

2

1

150. Brücher BLDM, Wieder H, Busch R, Becker K, Lordick F, Molls M, Siewert JR, Schwaiger M (2006) POSSIBLE INDIVIDUALIZED THERAPY BY EARLY ASSESSMENT OF RESPONSE DURING NEOADJUVANT RADIOCHEMOTHERAPY IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA PATIENTS BY 18-FDG-PET, *J Clin Oncol* 24(18), 4060-4060. DOI: https://ascopubs.org/doi/abs/10.1200/jco.2006.24.18_suppl.4060.

2005

151. Zimmermann F, Brücher BLDM, Becker K, Röthling N, Seroneit T, Riera J, Peschel C, Siewert JR, Molls M, Lordick F (2005) PRÄOPERATIVE RADIOCHEMOTHERAPIE (RTXCTX, OXALIPLATIN) BEI UT3-PLATTENEPITHELKARCINOMEN DES SUPRABIFURKALEN OESOPHAGUS, *Strahlentherapie & Onkologie, Band 181*, Nr.1, V8.03.
152. Zimmermann F, Brücher BLDM, Becker K, Lordick F, Grosu A, Stein HJ, Siewert JR, Molls M (2005) HISTOPATHOLOGISCHE REMISSIONSRATEN ALS PROGNOSTISCHER INDIKATOR NACH NEOADJUVANTER RTX/CTX DES PLATTENEPITHELKARCINOMS DES OESOPHAGUS, *Strahlentherapie & Onkologie, Band 181*, Nr.1, PV8.04.
153. Brücher BLDM, Becker K, Lordick F, Fink U, Sarbia M, Stein HJ, Busch R, Molls M, Höfler H, Siewert JR (2005) HISTOPATHOLOGISCHE RESPONSE MITTELS RESIDUALER TUMORZELLEN BEI PATIENTEN MIT PLATTENEPITHELKARCINOMEN DES OESOPHAGUS UND NEOADJUVANTER RADIOCHEMOTHERAPIE, *Z Gastroenterol* 43, 7938 (Abstract CP05).
154. Brücher BLDM, Zimmermann F, Riera-Knorrenschild J, Becker K, Röthling N, Seroneit T, Molls M, Siewert JR, Lordick F (2005) PHASE-I-STUDIE NEOADJUVANTER KONTINUIERLICHER INFUSION MIT 5-FLUOROURACIL UND ESKALIERUNGS-DOSIS VON OXALIPLATIN (OXA) WÖCHENTLICH MIT BEGLEITENDER STRAHLENTHERAPIE (RTX) BEI PATIENTEN MIT LOKAL FORTGESCHRITTENEN PLATTENEPITHELKARCINOMEN DES OESOPHAGUS (ESCC), *Z Gastroenterol* 43, 7938 (abstr. CP02).

155. Brücher, BLDM, Höfler Heinz, Siewert, Jörg R, Sarbia, M (2005) HYPERMETHYLIERUNG VON HMLH1, HPP1, P14ARF, P16INK4A UND APC BEI PRIMÄREN ADENOCARCINOMEN DES DÜNNDARMS, **Z Gastroenterol 43**, 7938 (abstr. P096).
156. Brücher BLDM, Wieder H, Lordick, F, Becker K, Zimmermann F, Weiss, W, Dittler HJ, Stein HJ, Fink U, Busch R, Molls M, Schwaiger M, Siewert JR (2005) FDG-PET ZUM MONITORING DER RESPONSE BEI PATIENTEN MIT PLATTENEPIHEL CARCINOMEN DES OESOPHAGUS UND NEOADJUVANTER RADIOCHEMOTHERAPIE, **Z Gastroenterol 43**, 7938.
157. Brücher BLDM, Zimmermann F, Riera J, Becker K, Roethling N, Seroneit T, Molls M, Peschel C, Siewert JR, Lordick F (2005) PHASE I TRIAL OF CONTINUOUS INFUSION 5-FLUOROURACIL (CI-5FU) AND ESCALATING DOSES OF OXALIPLATIN (OXA) GIVEN WEEKLY WITH CONCURRENT RADIATION (RT) IN LOCALLY ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC), **J Clin Oncol 23**(16), 4266-4266. DOI: https://ascopubs.org/doi/10.1200/jco.2005.23.16_suppl.4266.
- 2003 158. Brücher BLDM, Specht K, Stein HJ, Siewert JR, Höfler H (2003) CYCLIN D1 AS A PREDICTIVE MARKER IN PATIENTS WITH ESOPHAGEAL SQUAMOUS CELL CARCINOMA AND NEOADJUVANT RADIOCHEMOTHERAPY, **Proc Am Soc Clin Oncol 22**, 289.
- 2002 159. Theisen J, Stein HJ, Brücher BLDM, Prentl K, Feussner H, Siewert JR (2002) ZENKER DIVERTICULUM: CRICOPHARYNGEAL MYOTOMY WITH DIVERTICULOPEXY VERSUS DIVERTICULECTOMY, **Abstract Book Digestive Week / SSAT (abstr. 108007)**.
- 2001 160. Bartels H, Stein HJ, Feith M, Brücher BLDM, Fink U, Siewert JR (2001) DELAYED RECONSTRUCTION FOLLOWING ESOPHAGECTOMY IN HIGH RISK PATIENTS WITH ESOPHAGEAL CANCER, Abstract Book, **39th World Congress of Surgery of the ISS**.

1

1

3

161. Brücher BLDM, Stein HJ, Werner M, Siewert JR (2001) LYMPHATIC VESSEL INFILTRATION IS AN INDEPENDENT PROGNOSTIC FACTOR IN PRIMARY RESECTED PATIENTS WITH ESOPHAGEAL SQUAMOUS CELL CARCINOMA, Abstract Book, **39th World Congress of Surgery of the ISS.**

162. Brücher BLDM, Stein HJ, Fink U, Siewert JR (2001) NEOADJUVANTE RTX/CTX BEIM PLATTENEPIHELKARCINOM DES OESOPHAGUS: CHIRURGIE FÜR WEN? **78.Tagung Vereinigung Bayerischer Chirurgen 81.**

1999

163. Brücher BLDM, Weber W, Bauer M, Fink U, Werner M, Molls M, Schwaiger M, Siewert JR (1999) PET IM MONITORING BEI NEOADJUVANT VORBEHANDELTEN LOKAL FORTGESCHRITTENEN PLATTENEPIHELKARZINOMEN DES OESOPHAGUS, Otto-Götze-Preis-Sitzung, **76.Tagung Vereinigung Bayerischer Chirurgen 25.**

164. Brücher BLDM, Stein HJ, Fink U, Bartels H, Feussner H, Siewert JR (1999) ESOPHAGEAL CARCINOMA IN PATIENTS WITH ACHALASIA: INCIDENCE, PREVALENCE AND PROGNOSIS, Abstract Book, **38th World Congress of Surgery of the ISS.**

1998

165. Brücher BLDM, Stein HJ, Feussner H, Bartels H, Siewert JR (1998) ACHALASIE UND CARCINOM DES OESOPHAGUS, **75.Tagung Vereinigung Bayerischer Chirurgen 41.**

1997

166. Helmberger H, Brücher BLDM, Bartzsch O, Dittler HJ, Baum U, Schulte B, Fink U, Gerhardt P (1997) ADENOCARCINOMA OF THE GASTROESOPHAGEAL JUNCTION AND THE STOMACH: RESPONSE EVALUATION TO NEOADJUVANT CHEMOTHERAPY USING CT AND MRI, 2nd Gastric Cancer Congress, München, 27-30.04.1997, **Bologna: Monduzzi Editore S.p.A.**

2

1

1

Σ 152

- 2009 167. Brücher BLDM, Königsrainer A (2009) LEBERRESEKTION – WAS IST MACHBAR? **Unimed Science**. (Book Chapter).
- 2006 168. Brücher BLDM (2006) MALIGNNE DÜNNDARMTUMOREN. In: Siewert JR, Rothmund M, Schumpelick V Praxis der Viszeralchirurgie, Onkologische Chirurgie. **Springer, Berlin, Heidelberg, New York**, 611-620. (Book Chapter).
169. Vogelsang H, Brücher BLDM, Scheidhauer K, Fürst H, Negele T, Zimmermann F (2006): MALIGNNE TUMOREN DER SCHILDDRÜSE: THERAPIE VON METASTASEN UND REZIDIVEN. In: Göke B (ed) Manual Endokrine Tumoren des Tumorzentrum München. Empfehlungen zur Diagnostik, Therapie und Nachsorge. **W. Zuckschwerdt Verlag, München**, 58-64. (Book Chapter).
170. Weber WA, Ott K, Brücher BLDM, Avril N, Schwaiger M (2006) NUKLEARMEDIZIN: BIOLOGISCHE BILDGEBUNG UND RESPONSE-EVALUATION. In: Siewert JR, Rothmund M, Schumpelick V (eds) Praxis der Viszeralchirurgie: Onkologische Chirurgie. **Springer, Berlin, Heidelberg, New York**, 99-109. (Book Chapter).
171. Zimmermann F, Meining A, Lordick F, Sarbia M, Brücher BLDM (2006) ÖSOPHAGUS-PLATTENEPITHELKARZINOM. In: Sandler A (ed) Manual Gastrointestinale Tumoren des Tumorzentrum München. Empfehlungen zur Diagnostik, Therapie und Nachsorge. **Zuckschwerdt-Verlag, München**, 1-18. (Book Chapter).
172. Zimmermann F, Brücher BLDM (2006) APPLICATIONS IN ESOPHAGEAL AND GASTRIC CANCER, In: Brown JM, Mehta MP, Nieder C (Eds.): Multimodal Concepts for Integration of Cytotoxic Drugs. **Springer Verlag Berlin Heidelberg New York**, 197–213. (Book Chapter). DOI: 10.1007/3-540-35662-2_14

1

5

173. Brücher BLDM (2005) Maligne DÜNNDARMTUMOREN (KAPITEL 45), In Siewert JR, Harder F und Rothmund M (Eds.): Praxis der Viszeralchirurgie, Band Onkologische Chirurgie, 2. Auflage. **Springer Verlag Berlin Heidelberg New York**, 611-620. (Book Chapter).
174. Weber WA, Ott K, Brücher BLDM, Avril N, Schwaiger M (2005) BIOLOGISCHE BILDGEBUNG UND RESPONSE-EVALUATION (KAPITEL 8), In Siewert JR, Harder F und Rothmund M (Eds.): Praxis der Viszeralchirurgie, Band Onkologische Chirurgie, 2. Auflage. **Springer Verlag Berlin Heidelberg New York**, 99-111. (Book Chapter).
175. Brücher BLDM, Jung Ch, Krämling HJ, Petrides PE, Wiebecke B (2005) DÜNNDARMTUMOREN: EMPFEHLUNGEN ZUR DIAGNOSTIK, THERAPIE UND NACHSORGE – GASTROINTESTINALE TUMOREN. **Tumormanual des Tumorzentrums München**, 7. neu bearbeitete Auflage. (Book Chapter).
176. Zimmermann F, Meining A, Lordick F, Sarbia M, Brücher BLDM (2005) OESOPHAGUSCARCINOM. EMPFEHLUNGEN ZUR DIAGNOSTIK, THERAPIE UND NACHSORGE – GASTROINTESTINALE TUMOREN. **Tumormanual des Tumorzentrums München**, 7. neu bearbeitete Auflage. (Book Chapter).

177. Brücher BLDM (2001) MALIGNE DÜNNDARMTUMORE, In Siewert JR, Harder F und Rothmund M (Eds.): Praxis der Viszeralchirurgie, Band Onkologische Chirurgie, **Springer Verlag Berlin Heidelberg New York**, 619–628. (Book Chapter).
178. Weber W, Avril N, Brücher BLDM, Schwaiger M (2001) NUKLEARMEDIZIN – POSITRONENEMISSIONSTOMOGRAPHIE, In Siewert JR, Harder F und Rothmund M (Eds.): Praxis der Viszeralchirurgie, Band Onkologische Chirurgie. **Springer Verlag Berlin Heidelberg New York**, 108–120. (Book Chapter).

179. Gross M, Brücher BLDM, Jung Ch, Krämling HJ, Petrides PE, Wiebecke B (2001):
DÜNNDARMTUMOREN: EMPFEHLUNGEN ZUR DIAGNOSTIK,
THERAPIE UND NACHSORGE – GASTROINTESTINALE
TUMOREN, **Tumormanual des Tumorzentrums
München**, 6. neu bearbeitete Auflage, 197-202.
(Book Chapter).

2000

180. Weber W, Brücher BLDM, Avril N, Schwaiger M (2000) POSITRONEN-EMISSIONS-TOMOGRAPHIE, In Roder JD, Stein HJ und Fink U (Eds.): Therapien gastrointestinaler Tumoren. **Springer Verlag Berlin Heidelberg New York**. Seite 30 – 36. (Book Chapter).

181. Stein HJ, Brücher BLDM, Feith M, Fink U, Werner M, Molls M, Fink U, Roder JD (2000) OESOPHAGUSKARZINOM, In Roder JD, Stein HJ und Fink U (Eds.): Therapien gastrointestinaler Tumoren. Springer Verlag Berlin Heidelberg New York. Seite 187 – 207. (Book Chapter).

182. Brücher BLDM, von Schilling Ch, Werner M, Zimmermann F, Roder JD (2000) DÜNNDARMTUMOREN, In Roder JD, Stein HJ und Fink U (Eds.): Therapien gastrointestinaler Tumoren. **Springer Verlag Berlin Heidelberg New York**. Seite 328 – 335. (Book Chapter).

1997

183. Brücher BLDM, Krämling HJ, Petrides PE, Roder JD, Wiebecke B (1997): DÜNNDARMTUMORE. EMPFEHLUNGEN ZUR DIAGNOSTIK, THERAPIE UND NACHSORGE – GASTROINTESTINALE TUMOREN, **Tumormanual des Tumorzentrums München**, 5. Auflage, 211-217. (Book Chapter).

Munich & Cottbus, October 2022



Björn L.D.M. Brücher

3

1

Σ 18